Return to study ST001098 main page
MB Sample ID: SA074914
| Local Sample ID: | V138 |
| Subject ID: | SU001142 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Age Or Age Range: | 30-60 years old |
| Weight Or Weight Range: | 52.3-176.6 kg |
| Gender: | Male and female |
| Human Medications: | To be included in the study all participants had to be taking an atypical (second-generation) antipsychotic |
| Human Inclusion Criteria: | DSM IV diagnosis of a schizophrenia spectrum diagnosis who had been taking an atypical antipsychotic for at least 6 months, with no changes in antipsychotic regimen for 8 weeks preceding the baseline visit. Twenty age and sex matched obese and nonobese participants without mental health diagnoses were included to match the BMI range of the patients with schizophrenia as BMI controls. |
| Human Exclusion Criteria: | Current use of insulin, diagnosis of diabetes mellitus type 2 prior to antipsychotic exposure, active substance abuse diagnosis |
Select appropriate tab below to view additional metadata details:
Subject:
| Subject ID: | SU001142 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Age Or Age Range: | 30-60 years old |
| Weight Or Weight Range: | 52.3-176.6 kg |
| Gender: | Male and female |
| Human Medications: | To be included in the study all participants had to be taking an atypical (second-generation) antipsychotic |
| Human Inclusion Criteria: | DSM IV diagnosis of a schizophrenia spectrum diagnosis who had been taking an atypical antipsychotic for at least 6 months, with no changes in antipsychotic regimen for 8 weeks preceding the baseline visit. Twenty age and sex matched obese and nonobese participants without mental health diagnoses were included to match the BMI range of the patients with schizophrenia as BMI controls. |
| Human Exclusion Criteria: | Current use of insulin, diagnosis of diabetes mellitus type 2 prior to antipsychotic exposure, active substance abuse diagnosis |
Factors:
| Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
|---|---|---|---|---|
| V138 | SA074914 | FL011569 | Schizophrenia dx | Treatment |
Collection:
| Collection ID: | CO001136 |
| Collection Summary: | Fasting blood samples were collected via venipuncture into an additive-free vial and allowed to coagulate at room temperature for 30 minutes. They were then centrifuged for 15 minutes at 2500 rcf to obtain serum. Samples were frozen and -80C, thawed once for sample processing related to the parent study, then kept at -80C until processing for NMR and GC assays |
| Sample Type: | Blood (serum) |
| Storage Conditions: | -80℃ |
| Collection Vials: | Additive-free vacuatiner |
Treatment:
| Treatment ID: | TR001156 |
| Treatment Summary: | N/A (observational study) |
Sample Preparation:
| Sampleprep ID: | SP001149 |
| Sampleprep Summary: | Serum samples were subjected to a 1:1 methanol:choloroform extraction, then dried with a speedvac. Prior to fatty acid analysis, the lipid fractions were resuspended and purified by TLC prior to GC analysis. This is described in more detail in the attached document, with sample prep summaries for the NMR component of this study included as well. |
| Sampleprep Protocol ID: | EllingrodSamplePrepProtocol |
| Sampleprep Protocol Filename: | EllingrodSamplePrepProtocols.pdf |
| Extraction Method: | 1:1 methanol:chloroform |
| Sample Resuspension: | hexane |
| Sample Spiking: | C17:0 methyl ester |
Combined analysis:
| Analysis ID | AN001786 |
|---|---|
| Analysis type | MS |
| Chromatography type | GC |
| Chromatography system | Agilent 6890N |
| Column | Unspecified |
| MS Type | Other |
| MS instrument type | |
| MS instrument name | |
| Ion Mode | UNSPECIFIED |
| Units | nmol |
Chromatography:
| Chromatography ID: | CH001261 |
| Instrument Name: | Agilent 6890N |
| Column Name: | Unspecified |
| Chromatography Type: | GC |
MS:
| MS ID: | MS001649 |
| Analysis ID: | AN001786 |
| MS Type: | Other |
| Ion Mode: | UNSPECIFIED |
